However, in the presence of ICU restriction, for medical reasons or patient preference, analyses on the outcome ‘transfer to ICU’ are limited to patients without ICU restriction, which is likely to have been a particularly selected group. All analyses were stratified by ICU restriction. ), indicating changing characteristics of the ICU population over time ( Linschoten and Asselbergs, 2020). We think additional requirements need to be met before drawing the conclusion that HCQ is beneficial.įirst, the median age of patients at ICU admission decreased during the first wave of COVID-19 in the Netherlands, as illustrated by Dutch data from the CAPACITY registry ( Figure 1
Given the limited number of effective drugs available, these results are of utmost interest. With great interest, we read the observational study by Lammers et al., in which hydroxychloroquine (HCQ) was associated with a 53% risk reduction of transfer to the ICU in patients hospitalised with COVID-19 ( Lammers et al., 2020).
0 kommentar(er)
